AstraZeneca PLC AZN NDXPHARMA
Company Overview
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications; and Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Why Investors Should Care
Generates a return on equity of 22.0%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 16.0%.
Net profit has compounded at 46.0% per year over the last five years.
Trades at a P/E of 24.4, below the sector median of 25.2.
Maintains a net profit margin of 17.0%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $58.74B (+8.6% YoY); net profit $10.22B.
- Trailing 12 Months Year-on-year growth — revenue +6.4%, earnings +2.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 9.8%, profit CAGR 46.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 9.82% |
| 1 Year: | 6.40% |
Compounded Profit Growth
| 5 Years: | 45.96% |
| 1 Year: | 2.50% |
Stock Price Performance
| 1 Year: | +5.46% |
| 6 Months: | -16.23% |
| 3 Months: | -12.50% |
| 1 Month: | +1.01% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)46.41 · Neutral
P/E of 24.36 is below the sector median of 25.17 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 22.0%.
- Profit CAGR of 46.0% over 5 years.
- Generates positive free cash flow.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 608.52 | 32.79 | $225.00B | 0.32% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 13.59B | 14.46B | 15.19B | 15.50B | 15.29B |
| Cost of Revenue | - | 2.24B | 2.47B | 2.80B | 3.12B | 2.68B |
| Gross Profit | - | 11.35B | 11.98B | 12.39B | 12.38B | 12.61B |
| Operating Expenses | - | 7.67B | 8.48B | 8.81B | 9.41B | 8.36B |
| Operating Income | - | 3.67B | 3.51B | 3.58B | 2.98B | 4.25B |
| EBITDA | - | 5.04B | 4.96B | 5.23B | 4.38B | 5.67B |
| Interest Expense | - | 349.00M | 439.00M | 434.00M | 484.00M | 393.00M |
| Pretax Income | - | 3.40B | 3.13B | 3.24B | 2.63B | 3.91B |
| Tax Provision | - | 481.00M | 679.00M | 709.00M | 300.00M | 833.00M |
| Net Income | - | 2.92B | 2.45B | 2.53B | 2.33B | 3.08B |
| Diluted EPS | 0.96 | 1.87 | 1.57 | - | 1.49 | 1.97 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 44.35B | 45.81B | 54.07B | 58.74B |
| Cost of Revenue | - | 12.39B | 8.27B | 10.21B | 10.63B |
| Gross Profit | - | 31.96B | 37.54B | 43.87B | 48.11B |
| Operating Expenses | - | 27.45B | 28.82B | 33.62B | 34.78B |
| Operating Income | - | 4.51B | 8.72B | 10.25B | 13.33B |
| EBITDA | - | 9.09B | 13.42B | 15.44B | 19.51B |
| Interest Expense | - | 1.33B | 1.59B | 1.68B | 1.61B |
| Pretax Income | - | 2.50B | 6.90B | 8.69B | 12.40B |
| Tax Provision | - | -792.00M | 938.00M | 1.65B | 2.17B |
| Net Income | - | 3.29B | 5.96B | 7.04B | 10.22B |
| Diluted EPS | - | 2.11 | 3.81 | 4.50 | 6.54 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 96.48B | 101.12B | 104.03B | 114.07B |
| Current Assets | - | 22.59B | 25.05B | 25.83B | 28.72B |
| Cash & Equivalents | - | 6.17B | 5.84B | 5.49B | 5.71B |
| Inventory | - | 4.70B | 5.42B | 5.29B | 6.56B |
| Receivables | - | 7.21B | 8.41B | 8.30B | 10.24B |
| Total Liabilities | - | 59.42B | 61.95B | 63.16B | 65.36B |
| Current Liabilities | - | 26.29B | 30.54B | 27.87B | 30.62B |
| Long Term Debt | - | 22.96B | 22.36B | 26.51B | 24.71B |
| Total Debt | - | 29.14B | 28.41B | 30.11B | 29.15B |
| Total Equity | - | 37.04B | 39.14B | 40.79B | 48.67B |
| Shares Outstanding | - | 1.55B | 1.55B | 1.55B | 1.55B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 9.81B | 10.35B | 11.86B | 14.57B |
| Investing Cash Flow | - | -2.96B | -4.06B | -7.98B | -6.81B |
| Financing Cash Flow | - | -6.82B | -6.57B | -4.00B | -7.54B |
| Capital Expenditure | - | -2.57B | -3.78B | -4.59B | -5.91B |
| Free Cash Flow | - | 7.24B | 6.57B | 7.28B | 8.67B |
| Net Change in Cash | - | 25.00M | -286.00M | -115.00M | 223.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 72.1% | 82.0% | 81.1% | 81.9% |
| Operating Margin % | - | 10.2% | 19.0% | 19.0% | 22.7% |
| Net Margin % | - | 7.4% | 13.0% | 13.0% | 17.4% |
| ROE % | - | 8.9% | 15.2% | 17.2% | 21.0% |
| ROCE % | - | 6.4% | 12.4% | 13.5% | 16.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Investor AB | 3.33% | 51.59M | $8.39B |
| 2 | Vanguard Capital Management LLC | 2.93% | 45.39M | $7.38B |
| 3 | Capital International Investors | 2.23% | 34.58M | $5.63B |
| 4 | NORGES BANK | 2.18% | 33.86M | $5.51B |
| 5 | Capital World Investors | 1.94% | 30.08M | $4.89B |
| 6 | FMR, LLC | 1.86% | 28.90M | $4.70B |
| 7 | Wellington Management Group, LLP | 1.84% | 28.54M | $4.64B |
| 8 | Legal & General Group PLC | 1.66% | 25.75M | $4.19B |
| 9 | JPMORGAN CHASE & CO | 1.24% | 19.20M | $3.12B |
| 10 | Vanguard Asset Management, Ltd | 1.21% | 18.71M | $3.04B |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AZN
AZN Stock Down 20% in 6 Months: How to Play After Pipeline Setbacks - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxQaWUyN1gtQ29CQVMwdFhNUGJ6d3NSZW1GbGhqYkRmLTRsMjFWMndOdVgybFJkb1NOUFJTcVRVUnZlNm43TjIyLU5qVmZrREwwUmpYRWYwZ0dERy1sREVUVUItcUljTHVWcWg3amF4UlExNzhmNjU3VjdYUGpoblR3S3I4SnRkcGVUSzhPMg…
IONS, AZN Stocks Fall On Full Data From Failed Cardiomyopathy Trial — Jefferies Sees Neutral To Negative Readthrough To ALNY - Stocktwits
<a href="https://news.google.com/rss/articles/CBMikwJBVV95cUxQWUl5cEd4WmZaUWxoQUZqUGUzNW1aRjNVSm9GLXdVRGVEcjUwWDZqOTdHbEl6M3p0ZzlFamtyYjc3SW5mZFRnVkp2cWYxU1hha2xaekEwZUdGSHpKLVQyMV96MzJPdDRhV3ROMlFZcmdxWmI5SERJZzIzQ0tDOURnNk02cUtEX283UVZjRV…
AstraZeneca treatment cuts breast cancer progression risk by 56% - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPdVZqZlpRZVNJeGF5T2xPQlFGdHdjaTh2R0hWck1QM3JUaFRud2k5NUNsUlJpQWlLNm1mTjNPTHlDWXU3WVhvSkZNVnh0ZFpvLWQ3R0NLNVI5QVlTbFNOdkFTQko4Nko5aHkyWFFuVmRrN1JkdzYyenBmVFNhNVZZcjhmTEE2TU4zOHBtYk…
AstraZeneca (LSE:AZN) Stock Trades At a Discount Following Its 57% Run - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxOSFAyLVNDNWlxbXJjdXNpYWxRSUZSeVNPY3N3VTN6Nm0yRk9jRHFaSk15UXd3YW9GQXdKRElaV2JJNV9pcUg4bFhHY2kyS09MWTVxd0FRdjFHSGhmVHktN1dqbW5mQXFMVl82a3VKTVlEVUdQNXdkdkM2ajhITFRRTE9hc08wN0JDY3pTRV…
AZN Looks 9.4% Undervalued on GF Value™ Amid Strong Dividend Pro - GuruFocus
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxQVF9nSC12cjk0cmJXdlA0TUdQLU1pWm51b0piZjJRWjBDMktJR3FTQkRoWXhoOFBCRlpvSlV0ek9fNXVmcmNJSzU0TE52Z2FudzZJY05TVmRXWnJ1Vk5yYUlTZDRud0Z6TDJzMG5RT3BvOW1oRG5qeDlDX0pqcG1IMndlbk5OTGcyNEN1X0…
Deal or No Deal, AstraZeneca Stock Is a Bargain - WSJ
<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxQVjYyYlNzdWlTM3E3dU96dVZ6cVdxaXhoalZpMHBDaWxSUEx4d2llQUtBODAxUzgwX0p4S3ZqOWZjZDRvdVdaUWhFcERPVnN2Rzg2RzFJeWk0cWNEcXlmTWlCTkNwZTB3bFluSzlrM0I0MkNZdExwVWxZS3h6cnJSOXdEZDBrMm9USHZR?o…
AZN — Frequently Asked Questions
What is the current share price of AstraZeneca PLC (AZN)?
As of 2026-09-07 16:24 PDT, AstraZeneca PLC (AZN) trades at $162.70 on NYSE. Its 52-week range is $145.54 to $208.62.
What is the market capitalisation of AZN?
AstraZeneca PLC (AZN) has a market capitalisation of $252.33B on NYSE.
What is the P/E ratio of AZN?
AZN trades at a trailing price-to-earnings (P/E) ratio of 24.36. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 4.98.
Does AZN pay a dividend?
AstraZeneca PLC (AZN) currently offers a dividend yield of 1.98%.
What is the return on equity (ROE) of AZN?
AZN has a return on equity (ROE) of 21.96%. Its return on capital employed (ROCE) is 15.97%.
Is AZN a good stock to buy?
This page provides a data-driven analysis of AstraZeneca PLC (AZN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.